Form 4 for JSPR Jasper Therapeutics, Inc.

Accepted 2024-02-12 00:00:00 ET · period of report 2024-02-08 · accession 0000950170-24-014017 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
I	2024-02-12	2024-02-08	JSPR	Abingworth LLP	10%	P - Purchase	$12.95	+190.0K	1.07M	+22%	+$2.46M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Voting Common Stock	2024-02-08	P	A	190,000	$12.95	1,066,189	I See footnotes	—	—	(F1) The amount of Voting Common Stock reported herein reflects a 1-for-10 reverse stock split effected by the Issuer on January 4, 2024. (F3) The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV VII, but each disclaims beneficial ownership of such securities except to the extent of their pecuniary interest therein, if any. (F2) Reflects securities held of record by Abingworth Bioventures VII LP ("ABV VII"). ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII.